about
Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases.Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastasesDevelopment and validation of a model predicting short survival (death within 30 days) after palliative radiotherapy.Palliative radiotherapy with or without additional care by a multidisciplinary palliative care team in patients with newly diagnosed cancer: a retrospective matched pairs comparison.Palliative radiotherapy during the last month of life: Predictability for referring physicians and radiation oncologists.Impact of intense systemic therapy and improved survival on the use of palliative radiotherapy in patients with bone metastases from prostate cancer.Palliative Radiotherapy with or without Additional Care by a Multidisciplinary Palliative Care Team: A Retrospective Comparison.Survival prediction score: a simple but age-dependent method predicting prognosis in patients undergoing palliative radiotherapy.Palliative Radiotherapy in Cancer Patients with Increased Serum C-Reactive Protein Level.Does Time between Imaging Diagnosis and Initiation of Radiotherapy Impact Survival after Whole-Brain Radiotherapy for Brain Metastases?Development of a score predicting survival after palliative reirradiation.Oligometastatic non-small cell lung cancer: a significant entity outside of specialized cancer centers?Survival after palliative radiotherapy in geriatric cancer patients.A Four-Tiered Prognostic Score for Patients Receiving Palliative Thoracic Radiotherapy for Lung Cancer.Survival After Palliative Radiotherapy in Patients with Breast Cancer and Bone-only Metastases.Early palliative radiation therapy in patients with newly diagnosed cancer: Reasons, clinical practice, and survival.Tumor marker analyses in patients with brain metastases: patterns of practice and implications for survival prediction research.Estimating need for palliative external beam radiotherapy in adult cancer patients.Impact of early palliative interventions on the outcomes of care for patients with non-small cell lung cancer.Impact of systemic treatment on survival after whole brain radiotherapy in patients with brain metastases.Contribution of adverse events to death of hospitalised patientsManagement of patients with metastatic prostate cancer (mPC) in a rural part of North Norway with a scattered population: does living near the department of oncology translate into a different pattern of care and survival?Prognostic models predicting survival of patients with brain metastases: integration of lactate dehydrogenase, albumin and extracranial organ involvementExternal Validation of a Prognostic Score for Patients Receiving Palliative Thoracic Radiotherapy for Lung CancerFeasibility and efficacy of sequential systemic therapy for metastatic castration-resistant prostate cancer in a rural health care settingIs there a seasonal variation of survival after systemic chemotherapy for metastatic castration-resistant prostate cancer in a rural part of North Norway?Active anticancer treatment during the final month of life in patients with non-small cell lung cancerAdverse events in deceased hospitalised cancer patients as a measure of quality and safety in end-of-life cancer care
P50
Q33390088-5BED7483-82A7-497C-8C7F-308A194713B0Q33777534-B8940772-5258-4616-B964-59A47933593CQ35089641-6F5D5114-9119-4150-ABA4-DB917FC90C01Q35164910-40847C76-6722-481B-AB7B-09844F1DD7D9Q36334606-3039E72E-A6C8-478E-981A-17ECE4A43E79Q37288432-89F1406B-A643-4AC1-AC87-F37083D3C372Q37731423-7776EB69-8D25-44B6-B8E3-BA2FBB9C1DF6Q38632096-0C4B1D75-8F48-40C1-BCA1-C4E5ADD11DA4Q39449290-9CC278A1-0511-4D2B-8311-73352FB7552FQ40571923-31D5A38E-1543-408D-B722-071D478BDC58Q42207668-74E684C5-B979-4282-80C9-3BE1B0EB29B4Q42759242-4045461C-87AF-41D6-9146-DAE76B55074FQ44770515-1E3AE67B-6848-459B-BEF1-D8A3ED545F16Q47214374-F5F17805-2AD5-43FA-B28E-82345E917D29Q47954489-3014BAAA-9927-45BF-88C3-B1E5B553889CQ48255439-CC1C8D71-3F2D-435F-BB1A-0B8C085F2055Q48266423-99FA1742-4680-4B79-ABC5-38CBC65D45B1Q48663253-35B13F4F-0113-4AE8-9A55-6C9762CCBA2CQ53096925-82C2490F-69F0-4713-843C-726FEEADDF8AQ54367194-D7FD7E60-ED7B-4E0A-9B70-8E994DC4EE61Q64285896-BFBFD6E1-22CC-4294-8D88-C6088F645997Q64900607-6D20C054-0437-42F9-B326-FC516A9FC6A1Q87614646-42819028-6330-4CA3-AA74-FA5A54925F0DQ89256195-D27326E0-AFC8-49F7-BE27-83F6E6C0074BQ89855122-45113A39-3D47-49E0-9D66-E786D95DCFCEQ90458058-BCCDAB13-6C14-4132-B57E-BFC0D49B48BBQ95525542-8C079AFF-7C43-4A92-BAB3-15898C204753Q96121248-815118CD-2AA1-46E7-B2BE-2F17B47925A6
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-5697-2218
@en
name
Ellinor Haukland
@ast
Ellinor Haukland
@en
Ellinor Haukland
@es
Ellinor Haukland
@nl
type
label
Ellinor Haukland
@ast
Ellinor Haukland
@en
Ellinor Haukland
@es
Ellinor Haukland
@nl
prefLabel
Ellinor Haukland
@ast
Ellinor Haukland
@en
Ellinor Haukland
@es
Ellinor Haukland
@nl
P106
P31
P496
0000-0002-5697-2218